{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:22:24Z","timestamp":1771456944703,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ANRS-MIE"},{"name":"Agence Nationale de Recherche sur le Sida et les h\u00e9patites virales-Maladies Infectieuse Emergentes"},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Many studies have reported weight gain in ART-naive people living with HIV (PWH) initiating an integrase strand-transfer inhibitor-based regimen. We studied the impact of early or advanced presentation and that of individual drugs in PWH initiating combined ART (cART) between 2012 and 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From the French Hospital Database HIV cohort, we assessed factors associated with a weight gain \u200a\u226510%, weight change after cART initiation or BMI increase \u200a\u22655 kg\/m2 up to 30 months. The analyses were conducted overall, and among PWH with early (primary infection or CD4 &amp;gt;350\/mm3 and viral load\u200a &amp;lt;100\u200a000 copies\/mL, without AIDS) and advanced presentation (AIDS or CD4 &amp;lt;200\/mm3, not during primary infection).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 30 months, 34.5% (95% CI: 33.5\u201335.6) of the 12\u200a773 PWH had a weight gain \u226510%, with 20.9% (95% CI: 19.6\u201322.2) among the 5794 with early presentation and 63.1% (95% CI: 60.9\u201365.3) among the 3106 with advanced presentation. Weight gain was 2.8 kg (95% CI: 2.0\u20133.7) for those with early presentation and 9.7 kg (95% CI: 8.4\u201311.1) for those with advanced presentation. Most weight gain occurred in the first 12 months. Underweight and obese PWH were at significantly higher risk of a BMI increase \u200a\u22655 kg\/m2 than normal-weight PWH. Results differed within classes and by outcome. Raltegravir and dolutegravir were consistently associated with greater weight gain than the other third agents. Tenofovir alafenamide was also associated with higher weight gain than tenofovir disoproxil or abacavir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>After initiating cART, PWH with early presentation exhibited a small weight gain, whereas it was large among those with advanced presentation. The choice of ART should account for the risk of weight gain, especially for PWH who present with advanced disease and\/or are obese.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkad007","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T06:09:35Z","timestamp":1674454175000},"page":"757-768","source":"Crossref","is-referenced-by-count":20,"title":["Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-4261","authenticated-orcid":false,"given":"Sophie","family":"Grabar","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital St Antoine , F75012, Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Potard","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , F75013, Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Piroth","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, CHU Dijon, and Inserm CIC 1432 Universit\u00e9 de Bourgogne , Dijon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Abgrall","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital B\u00e9cl\u00e8re, Service de M\u00e9decine Interne, Clamart, and Universit\u00e9 Paris-Saclay, CESP INSERM U1018 , Le Kremlin-Bic\u00eatre , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bernard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Tours , Tours , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, INSERM EA1413 , CHU de Nantes, Nantes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Caby","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , F75013, Paris , France"},{"name":"Unit\u00e9 VIH-IST, Service d\u2019Immuno-Hematologie , H\u00f4pital Victor Dupouy, Argenteuil , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"de Truchis","sequence":"additional","affiliation":[{"name":"AP-HP H\u00f4pital Raymond Poincar\u00e9, Universit\u00e9 Paris-Saclay , Garches , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Necker-Enfants Malades, Service de Maladies Infectieuses et Tropicales, Centre d\u2019Infectiologie Necker-Pasteur , Paris , France"},{"name":"IHU Imagine , Paris , France"},{"name":"Institut Cochin\u2014CNRS 8104\u2014INSERM U1016, Universit\u00e9 Paris Cit\u00e9 , Paris , France"},{"name":"Institut Pasteur, Centre M\u00e9dical de l\u2019Institut Pasteur , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Enel","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, Public Health Department, Marseille, and Aix-Marseille University, CEReSS, Health Service Research and Quality of Life Center , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"AP-HP, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, and AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Aude","family":"Khuong","sequence":"additional","affiliation":[{"name":"H\u00f4pital Delafontaine , Saint-Denis , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, AP-HP, H\u00f4pital Cochin, INSERM, CIC 1417 , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Matheron","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat-Claude Bernard, GHU Paris Nord, AP-HP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Melica","sequence":"additional","affiliation":[{"name":"Clinical Immunology and Infectious Diseases Department, Henri Mondor Hospital , Creteil , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Melliez","sequence":"additional","affiliation":[{"name":"M\u00e9decine Interne, H\u00f4pital Riaumont , 62 800, Li\u00e9vin , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Meynard","sequence":"additional","affiliation":[{"name":"AP-HP, Department of Infectious Diseases, Saint-Antoine Hospital , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Pavie","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, AP-HP H\u00f4tel-Dieu , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Slama","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, H\u00f4tel Dieu Hospital, APHP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Bregigeon","sequence":"additional","affiliation":[{"name":"Aix-Marseille Universit\u00e9, APHM, H\u00f4pital Sainte-Marguerite , Marseille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3617-5411","authenticated-orcid":false,"given":"Pierre","family":"Tattevin","sequence":"additional","affiliation":[{"name":"Maladies Infectieuses et R\u00e9animation M\u00e9dicale, H\u00f4pital Pontchaillou, Centre Hospitalo-Universitaire , Rennes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN) , F75012, Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-0869","authenticated-orcid":false,"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , F75013, Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"2023030208091491400_","author":"European AIDS Clinical Society Guidelines","year":"2021"},{"key":"2023030208091491400_","author":"Department of Health and Human Services","year":"2021"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Namsal Anrs Study Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25732","article-title":"Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study","volume":"24","author":"Martinez-Sanz","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s15010-019-01376-5","article-title":"Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir\/ritonavir","volume":"48","author":"Calza","year":"2020","journal-title":"Infection"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3018(21)00163-6","article-title":"Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium","volume":"8","author":"Bansi-Matharu","year":"2021","journal-title":"Lancet HIV"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/QAI.0000000000002556","article-title":"Brief report: weight gain following ART initiation in ART-naive people living with HIV in the current treatment era","volume":"86","author":"Ruderman","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/QAD.0000000000002900","article-title":"Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir\/maraviroc","volume":"35","author":"Bastard","year":"2021","journal-title":"AIDS"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cells11111841","article-title":"Inhibition of adipose tissue beiging by HIV integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes","volume":"11","author":"Ngono Ayissi","year":"2022","journal-title":"Cells"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/QAD.0000000000003289","article-title":"Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens","volume":"36","author":"Milic","year":"2022","journal-title":"AIDS"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Global BMI Mortality Collaboration","year":"2016","journal-title":"Lancet"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ije\/dyu002","article-title":"Cohort profile: French hospital database on HIV (FHDH-ANRS CO4)","volume":"43","author":"Mary-Krause","year":"2014","journal-title":"Int J Epidemiol"},{"key":"2023030208091491400_","author":"The ANRS CO4 French Hospital Database on HIV"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/QAD.0000000000002644","article-title":"Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir\/etravirine","volume":"34","author":"Assoumou","year":"2020","journal-title":"AIDS"},{"key":"2023030208091491400_","volume-title":"SAS for Mixed Models","author":"Littell","year":"2006"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu040","article-title":"Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV cohort study","volume":"1","author":"Hasse","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/QAI.0b013e31825c3a68","article-title":"Adipogenic\/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden","volume":"61","author":"Vidal","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/QAD.0000000000002168","article-title":"Impact of HIV\/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis","volume":"33","author":"Gorwood","year":"2019","journal-title":"AIDS"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/cells9040854","article-title":"SIV infection and the HIV proteins Tat and Nef induce senescence in adipose tissue and human adipose stem cells, resulting in adipocyte dysfunction","volume":"9","author":"Gorwood","year":"2020","journal-title":"Cells"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e31829cfbfa","article-title":"Impact of late presentation on the risk of death among HIV-infected people in France (2003\u20132009)","volume":"64","author":"Montlahuc","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/cid\/civ192","article-title":"Weight change after antiretroviral therapy and mortality","volume":"60","author":"Yuh","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023030208091491400_","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023030208091491400_","article-title":"Surveillance du VIH et des IST bact\u00e9riennes","author":"Sant\u00e9 Publique France"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/3\/757\/49376398\/dkad007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/3\/757\/49376398\/dkad007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T03:28:18Z","timestamp":1701660498000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/3\/757\/6997637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad007","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,2]]},"published":{"date-parts":[[2023,1,23]]}}}